'He Was a Person Who Never Gave Up'
An old friend talks about Judah Folkman, the pioneering cancer researcher who endured years of skepticism before his work was recognized as the breakthrough it truly was.
Dr. James Mandell, CEO of Children's Hospital Boston, trained under Judah Folkman and was his friend for 30 years. Folkman died of a heart attack on Monday at age 74. NEWSWEEK's Claudia Kalb spoke with Mandell about Folkman's approach to life and work. Excerpts:
NEWSWEEK: How are you all doing?
Clearly, this was not expected. He'd been as vibrant last week as he was 10 years before and 10 years before that. We were really not expecting this at all.
Did he have any known heart issue?
No. He's been great, flying everywhere, active at all the international and national meetings.
What was his legacy?
He was a person who never gave up. He always encouraged us as well as his own lab to continue to look for solutions to the questions that came up, specifically in areas that involved patients. He was always the one who said, "What are the problems you see in the patients? What are the unanswered questions? Let's take them back to the lab and figure them out." That's one huge legacy: the relentlessness and orientation toward a solution. Second was his mentorship. Every one of us feels we were mentored by him. He was the kind of person who really inspired you. It wasn't a matter of drudgery or completion of a task; it was about conception, ideas, following through.
He inspired people outside his lab as well?
Everywhere. They're scattered now all across the industry, across the institutions, the world—people who trained under him or were influenced by him.
Did he talk about the personal trials, the early skepticism he endured?
Yes. I was here as a trainee, so I was in one of his offices in the '70s. I think that he looked at that as just a fact of life. He never thought that innovative ideas were easily accepted, and if they were, they probably weren't very innovative. I don't think he took it personally. He had a wonderful sense of optimism. That really followed over to those of us who were ourselves starting our careers.
Has science changed because of him?
I think the institution changes you and you change the institution. I think the fact that you take care of children and deal with these wonderful magical beings, you tend to be optimistic. You always look for ways to improve things. I think he, especially, was the kind of person who was so inquisitive that he would never, ever stand on any accepted pattern of treatment or role of science in medicine. He was the questioner. He imbued that optimism with a real sense of realism. You have to go back, figure out basic mechanisms. Even if something doesn't work perfectly the first time you try it. It's always a step in the process.
How did he balance work with family?
He was a great role model for that. He lived across the street from us. We would always talk. He would work the weirdest hours, one or two in the morning. He always felt that the family was important. It's what gave me leave when I became older to spend time with my grandchildren. I think he was a real example for that. How you always take precious time for your family even though you work exceptionally hard.
What about the work he had left to do?
I think he felt he had 20 years ahead of him, and so did we. That's part of the crushing part of this. It's clear that his work is in process. A lot of the work, the most recent focus on the diagnosis and prevention of early malignancies before they could be seen—that's what he was working on the last several years, and a lot of investigators who grew up in his laboratory will continue that work. That doesn't mean we won't miss him every day.
Many people believed he should have won the Nobel Prize.
Clearly, this is somebody who founded a field of science that didn't exist, persevered through all of the skepticism until it became a science in which there are tens of thousands of articles on a regular basis and tens of hundreds of patients exposed to treatments. So clearly we thought recognition of this as a world-changing event was appropriate. I wish Judah would have lived long enough to see that happen.
Like The Daily Beast on Facebook and follow us on Twitter for updates all day long.
Claudia Kalb, who writes health and medical stories for the magazine, was named senior writer in December 2004. Kalb has reported on a wide range of medical and scientific issues, including stem cells, autism, reproductive medicine, HIV/AIDS and childhood obesity. Her cover stories for the magazine include “Kids and the Growing Food Allergy Threat” (October 2007); “Girl or Boy? Now You can Choose. But Should You?” (January 2004), which won a Front Page Award from the Newswomen’s Club of New York; and “SARS: What You Need to Know, The New Age of Epidemics” (May 2003). Kalb’s story “Battling a Black Epidemic” was featured in Newsweek’s special report, “AIDS at 25” (May 2006), which was a National Magazine Award finalist in 2007.
Kalb had been a general editor in New York since 1999 and a correspondent in the Boston bureau since 1996, where she covered medicine, politics, education, and family and social issues.
Prior to joining Newsweek in 1994, Kalb worked as a researcher and reporter at the Freedom Forum Media Studies Center in New York, where she researched books, including Dictatorship of Virtue by then New York Times writer Richard Bernstein and Den of Lions by former Lebanon hostage Terry Anderson.
Kalb was awarded a Casey fellowship at the Casey Journalism Center for Children and Families (June 1998), a Knight mini-fellowship at the Knight Science Journalism Fellowships at MIT (December 1999) and a John S. Knight Fellowship at Stanford University for the academic year 2001-2002.
Kalb received her B.A. and graduated magna cum laude from Amherst College before earning her Master’s degree in international affairs from Columbia University. She works in Newsweek’s Washington bureau.
For inquiries, please contact The Daily Beast at editorial@thedailybeast.com.




Comments